Huma Therapeutics raises $130m in Series C funding led by Leaps by Bayer and Hitachi Ventures to scale its digital health platform.
The Series C financing was led by Leaps by Bayer and Hitachi Ventures to support international expansion and platform development.
Huma Therapeutics provides a digital health platform that powers virtual hospitals at home and supports decentralized clinical trials. The modular technology combines predictive algorithms and real-world data to advance proactive care.
Huma Therapeutics has secured $130m in a Series C funding round to expand its remote patient monitoring platform internationally. The investment was led by Leaps by Bayer and Hitachi Ventures, with participation from several new strategic and financial backers including Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures and HAT. The capital will be deployed to scale the company's digital health infrastructure across the United States, Asia and the Middle East.
The financing also includes an agreement for a further $70m commitment that can be exercised at a later date. Goldman Sachs International served as the lead placement agent for the transaction, with HSBC Bank plc and Nomura acting as joint placement agents.
From the founder
"This is a significant moment in Huma’s history and I will work to build enduring, trusted relationships with our new partners. We are living through unprecedented times and the importance of health and well-being is underlined as never before. Together with our partners we can use our expertise, technology, and innovation to change the face of healthcare and research and impact people’s health everywhere."
Alan Milburn
Chairman of Huma’s Board at Huma Therapeutics
Investor perspective
"Aligned with the vision of Leaps by Bayer, Huma’s expertise and technology will help drive a global paradigm shift towards prevention and care and may boost research efforts using data and digital technology. We invest into the most disruptive technologies of our time that have the potential to change the world for the better. As an early investor into Huma we know how perfectly the company fits into that frame as one of the leading digital innovators in healthcare and lifesciences."
Juergen Eckhardt
EVP, Head of Leaps by Bayer and Pharmaceuticals Business, Development & Licensing, Leaps by Bayer
Use of funds
- 01Expand into international markets
Investors
Juergen Eckhardt
Leaps by Bayer
Hitachi Ventures
Jonathan Machado
Samsung Next
Gen Tsuchikawa
Sony Innovation Fund by IGV
Unilever Ventures
HAT Technology & Innovation Fund
Nomura
Categories
About the company
Huma Therapeutics
Huma Therapeutics develops a modular digital health platform for virtual hospital care and decentralized clinical trials.